Inventor · disambiguated record
Gregory Sieczkiewicz
Also filed as: SIECZKIEWICZ GREGORY · SIECZKIEWICZ GREGORY J · SIECZKIEWICZ GREGORY JAMES
12 granted patents·13 pending applications·450 citations·filing 2010–2024
92Inventor score
Top patents by PatentIndex Score
25 records- 0198US8710200B2Engineered nucleic acids encoding a modified erythropoietin and their expressionSCHRUM JASON P·Filed 2012·Granted Apr 29, 2014·382 cites·14 claims
- 0297US11028142B2Compositions and methods for TCR reprogramming using fusion proteinsTCR2 THERAPEUTICS INC·Filed 2020·Granted Jun 8, 2021·6 cites·30 claims
- 0396US10442849B2Compositions and methods for TCR reprogramming using fusion proteinsTCR2 THERAPEUTICS INC·Filed 2017·Granted Oct 15, 2019·21 cites·27 claims
- 0496US10208285B2Compositions and methods for TCR reprogramming using fusion proteinsTCR2 THERAPEUTICS INC·Filed 2018·Granted Feb 19, 2019·14 cites·20 claims
- 0595US11085021B2Compositions and methods for TCR reprogramming using fusion proteinsTCR2 THERAPEUTICS INC·Filed 2020·Granted Aug 10, 2021·3 cites·27 claims
- 0693US10358474B2Compositions and methods for TCR reprogramming using fusion proteinsTCR2 THERAPEUTICS INC·Filed 2018·Granted Jul 23, 2019·9 cites·30 claims
- 0792US11242376B2Compositions and methods for TCR reprogramming using fusion proteinsTCR2 THERAPEUTICS INC·Filed 2017·Granted Feb 8, 2022·6 cites·19 claims
- 0891US9701965B2Engineered nucleic acids and methods of use thereofMODERNATX INC·Filed 2014·Granted Jul 11, 2017·4 cites·16 claims
- 0988US10358473B2Compositions and methods for TCR reprogramming using fusion proteinsTCR2 THERAPEUTICS INC·Filed 2018·Granted Jul 23, 2019·4 cites·30 claims
- 1088US2024301026A1Compositions and methods for tcr reprogramming using fusion proteinsTCR2 THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1184US11965012B2Compositions and methods for TCR reprogramming using fusion proteinsTCR2 THERAPEUTICS INC·Filed 2022·Granted Apr 23, 2024·0 cites·27 claims
- 1284US11377638B2Compositions and methods for TCR reprogramming using fusion proteinsTCR2 THERAPEUTICS INC·Filed 2018·Granted Jul 5, 2022·1 cites·19 claims
- 1377US2022298478A1Compositions and methods for tcr reprogramming using fusion proteinsTCR2 THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1476US2021236655A1Engineered Nucleic Acids and Methods of Use ThereofMODERNATX INC·Filed 2020·Application pending·0 cites
- 1571US2021206827A9Compositions and methods for tcr reprogramming using fusion proteinsTCR2 THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 1670US2018112221A1Engineered Nucleic Acids and Methods of Use ThereofMODERNATX INC·Filed 2017·Application pending·0 cites
- 1768US12241062B2Mammalian cells and methods for engineering the same64 X INC·Filed 2023·Granted Mar 4, 2025·0 cites·20 claims
- 1865US2012237975A1Engineered nucleic acids and methods of use thereofSCHRUM JASON·Filed 2011·Application pending·0 cites
- 1956US2024052341A1Mammalian cells and methods for engineering the same64 X INC·Filed 2021·Application pending·0 cites
- 2049US2021079057A1Compositions and methods for tcr reprogramming using fusion proteinsTCR2 THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 2148US2014206752A1Engineered nucleic acids and methods of use thereof for non-human vertebratesmodeRNA Therapeutics·Filed 2012·Application pending·0 cites
- 2245US2016256572A1Engineered nucleic acids and methods of use thereof for non-human vertebratesMODERNA THERAPEUTICS INC·Filed 2016·Application pending·0 cites
- 2344US2014371302A1Modified mrnas encoding cell-penetrating polypeptidesMODEMA THERAPEUTICS INC·Filed 2012·Application pending·0 cites
- 2433US2012269765A1Cytokine compositions and methods of use thereofGARCIA K CHRISTOPHER·Filed 2010·Application pending·0 cites
- 2528US2013064788A1Il-17 family cytokine compositions and usesBARNES THOMAS M·Filed 2010·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Gregory Sieczkiewicz files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →